Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15711502 | 0.83 | CA12 (0.36) | CA12CA2CA9MAPTLMNA | |
| SCHEMBL20034048 | 0.80 | KDM4E (0.45) | CA12CA2CA9ALDH1A1MAPT | |
| SCHEMBL12794511 | 0.78 | CA12 (0.32) | CA12CA2CA9NFE2L2 | |
| SCHEMBL14045692 | 0.78 | CA12 (0.36) | CA12CA2CA9ALDH1A1MAPT | |
| SCHEMBL15966239 | 0.78 | ALDH1A1 (0.41) | CA12CA2CA9ALDH1A1MAPT | |
| SCHEMBL15181196 | 0.78 | CA12 (0.41) | CA12CA2CA9ALDH1A1MAPT | |
| SCHEMBL21755864 | 0.78 | CA12 (0.46) | CA12CA2CA9ALDH1A1MAPT | |
| SCHEMBL15497903 | 0.78 | CA12 (0.46) | CA12CA2CA9ALDH1A1MAPT | |
| SCHEMBL17591558 | 0.75 | NFE2L2 (0.41) | ALDH1A1MAPTKDM4ELMNANFE2L2 | |
| SCHEMBL333121 | 0.75 | NFE2L2 (0.41) | ALDH1A1MAPTKDM4ELMNANFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-9995865-B2 | Phase difference plate, circularly polarizing plate, and image display device | ZEON CORPORATION (JP) | 2018-06-12 | — | — | US | disclosed |
| US-9951010-B2 | Compounds as CRTH2 antagonist and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-9828373-B2 | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-11-28 | — | — | US | disclosed |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| WO-2017132173-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | CA12 1281/4885CA2 3421/4885CA9 1566/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CA12 4416/4885CA2 4527/4885CA9 4775/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | CA12 4845/4885CA2 4675/4885CA9 4604/4885 |
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | CDK6, CDK4, CDK7 | CA12 4865/4885CA2 4027/4885CA9 4270/4885 |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XPOT, XPO1, XPO5 | CA12 4866/4885CA2 4591/4885CA9 4690/4885 |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | CA12 4866/4885CA2 4591/4885CA9 4690/4885 |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | HRH2, PTGDR2, HRH1 | CA12 4233/4885CA2 1985/4885CA9 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.